Hyderabad-based pharmaceutical manufacturer Granules India Limited announced its consolidated financial results for the second quarter ended September 30, 2026. The company posted a robust 39.2% year-on-year (YoY) increase in net profit, reaching Rs. 182 crore, compared to Rs. 131 crore in the corresponding period of the previous fiscal year.

Operational revenue grew 20.3% YoY to a record Rs. 1,560 crore, driven by finished dosages (73% of revenue), APIs (13%), and PFIs (10%), with North America contributing 72%. EBITDA rose 21.3% to Rs. 337.4 crore with a stable 21.6% margin, despite logistics pressures from West Asian geopolitical tensions. Warrant proceeds helped transition the company into a net cash reserve of Rs. 828 crore.

Commenting on the results, Dr. Krishna Prasad Chigurupati, Chairman & Managing Director of Granules India Limited said, “We filed two potential first-to-file ANDAs in H1, which makes it a total of three potential first to file ANDAs and continue to shift towards complex generics and peptide CDMO. With the balance warrant proceeds received, we hold net cash of ₹828 Cr to invest in R&D, manufacturing and quality”.